Table 2. Subgroup Analyses
PTA‐BMSDESP Valuea
Total (n)Event (n)% (95% CI)Total (n)Event (n)% (95% CI)
5‐year major amputation/death rate per patient
DM433481.0 (68.8–93.2)442668.3 (52.2–84.4)0.07
No DM211578.2 (58.0–98.4)291968.9 (50.7–87.1)0.56
Tissue loss564583.0 (72.6–93.4)634171.3 (58.8–83.8)0.05
No tissue loss8450.0 (15.3–84.7)10447.5 (11.0–84.0)0.59
Impaired RF10990.0 (71.4–100)11656.4 (26.0–86.8)0.017
Normal RF544077.9 (65.9–89.9)623970.9 (57.8–84.0)0.18
1 lesion463578.9 (66.4–91.4)402674.9 (58.8–91.0)0.36
2 lesions9888.9 (68.3–100)191056.1 (31.6–80.6)0.09
3 lesions9672.2 (40.4–100)14964.3 (39.2–89.4)0.45
5‐year event rate per patient
DM433684.7 (73.7–95.7)442975.1 (60.2–90.0)0.15
No DM211786.4 (69.9–100)292072.8 (55.2–90.4)0.30
Tissue loss564785.7 (76.1–95.3)634577.7 (66.1–89.3)0.13
No tissue loss8675.0 (45.0–100)10447.5 (11.0–84.0)0.09
Impaired RF10990.0 (71.4–100)11656.4 (26.0–86.8)0.017
Normal RF544483.9 (73.5–94.3)624377.6 (65.3–89.9)0.20
1 lesion463883.9 (72.9–94.9)402775.6 (59.9–91.3)0.25
2 lesions99100 (100–100)191268.4 (43.9–92.9)0.07
3 lesions9672.2 (40.4–100)141071.4 (47.7–95.1)0.66
  • BMS indicates bare metal stent; DES, drug‐eluting stent; DM, diabetes mellitus; N, number of patients; PTA, percutaneous transluminal angioplasty, RF, renal function.

  • a Overall log‐rank test.